Clinical efficacy of and switch from T helper 2 to T helper 1 cytokine profile after interferon alpha2a monotherapy for human echinococcosis

Clin Infect Dis. 1999 Jul;29(1):205-6. doi: 10.1086/520157.

Authors

S Harraga¹, V Godot, S Bresson-Hadni, C Pater, I Beurton, B Bartholomot, D A Vuitton

Affiliation

¹ WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, Faculté de Médecine et de Pharmacie, Université de Franche-Comté, Besançon, France.

PMID: 10433588
DOI: 10.1086/520157

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antiviral Agents / therapeutic use*
Cytokines / blood*
Echinococcosis, Hepatic / blood
Echinococcosis, Hepatic / complications
Echinococcosis, Hepatic / drug therapy*
Echinococcosis, Hepatic / immunology*
Hepatitis C / blood
Hepatitis C / complications
Hepatitis C / drug therapy
Hepatitis C / immunology
Humans
Interferon alpha-2
Interferon-alpha / therapeutic use*
Interferon-gamma / blood
Interleukin-10 / blood
Interleukin-4 / blood
Interleukin-5 / blood
Recombinant Proteins
Th1 Cells / immunology*
Th2 Cells / immunology*

Substances

Antiviral Agents
Cytokines
Interferon alpha-2
Interferon-alpha
Interleukin-5
Recombinant Proteins
Interleukin-10
Interleukin-4
Interferon-gamma